Last reviewed · How we verify
insulin degludec/insulin aspart — Competitive Intelligence Brief
phase 3
Small molecule
Live · refreshed every 30 min
Target snapshot
insulin degludec/insulin aspart (insulin degludec/insulin aspart) — Novo Nordisk A/S.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| insulin degludec/insulin aspart TARGET | insulin degludec/insulin aspart | Novo Nordisk A/S | phase 3 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- insulin degludec/insulin aspart CI watch — RSS
- insulin degludec/insulin aspart CI watch — Atom
- insulin degludec/insulin aspart CI watch — JSON
- insulin degludec/insulin aspart alone — RSS
Cite this brief
Drug Landscape (2026). insulin degludec/insulin aspart — Competitive Intelligence Brief. https://druglandscape.com/ci/insulin-degludec-insulin-aspart. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab